Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: A multicenter, randomized, sham device-controlled, double-blind study

American Journal of Clinical Dermatology

Volumn 15, Issue 2, 2014, Pages 115-127

  Jimenez, Joaquin J ^a   Wikramanayake, Tongyu C ^a   Bergfeld, Wilma ^b   Hordinsky, Maria ^c   Hickman, Janet G ^d   Hamblin, Michael R ^e,f,g   Schachner, Lawrence A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d The Education and Research Foundation Inc   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABNORMAL SENSATION; ADULT; APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; DEVICE APPROVAL; DIGITAL IMAGING; DOUBLE BLIND PROCEDURE; DRY SKIN; FEMALE; FEMALE PATTERN HAIR LOSS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAIR GROWTH; HAIR LOSS; HUMAN; LASER; LOW LEVEL LASER DEVICE; LOW LEVEL LASER SYSTEM; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCALP; SELF EVALUATION; SHAM PROCEDURE; SKIN IRRITATION; THERAPY EFFECT; TREATMENT DURATION; ALOPECIA; CLINICAL TRIAL; DEVICES; GROWTH, DEVELOPMENT AND AGING; HAIR; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ALOPECIA; DOUBLE-BLIND METHOD; FEMALE; HAIR; HUMANS; LASER THERAPY, LOW-LEVEL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84899701624     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0060-6     Document Type: Article

References (39)

1. Olsen EA, Messenger AG, Shapiro J, Bergfeld WF, Hordinsky MK, Roberts JL, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301-11.
2. Hoffmann R, Happle R. Current understanding of androgenetic alopecia: Part I. Etiopathogenesis. Eur J Dermatol. 2000;10(4):319-27.
3. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184-9.
4. McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett. 2012;17(6):1-4.
5. Rangwala S, Rashid RM. Alopecia: a review of laser and light therapies. Dermatol Online J. 2012;18(2):3.
6. Avram MR, Rogers NE. The use of low-level light for hair growth: part I. J Cosmet Laser Ther. 2009;11(2):110-7.
7. Lanzafame RJ, Blanche RR, Bodian AB, Chiacchierini RP, Fernandez-Obregon A, Kazmirek ER. The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med. 2013;45(8):487-95.
8. Leavitt M, Charles G, Heyman E, Michaels D. HairMax Laser-Comb laser phototherapy device in the treatment of male androgenetic alopecia: a randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29(5):283-92.
9. Satino JL, Markou M. Hair regrowth and increased hair tensile strength using the HairMax LaserComb for low-level laser therapy. Int J Cosmetic Surg Aesthetic Dermatol. 2003;5(2):113-7. (Pubitemid 37314030)
10. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-65.
11. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3):247-54. (Pubitemid 8208166)
12. Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768-76.
13. Savin R. Evaluating androgenetic alopecia in male and female patients: an improved visual method of classifying and tracking hair loss using computer-generated male and female pattern and density scales. Kalamazoo: The Upjohn Company; 1994.
14. Fitzpatrick TB, Ortonne J-P. Normal skin color and general consideration of pigmentary disorders. In: Freedberg IM, Eisen Z, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill; 2003. p. 819-26.
15. Bjordal JM, Couppe C, Chow RT, Tuner J, Ljunggren EA. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Aust J Physiother. 2003;49(2):107-16. (Pubitemid 36705726)
16. Brosseau L, Welch V, Wells G, et al. Low level laser therapy (classes I, II and III) in the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2000(2):CD002049.
17. Cauwels RG, Martens LC. Low level laser therapy in oral mucositis: a pilot study. Eur Arch Paediatr Dent. 2011;12(2):118-23.
18. Christie A, Jamtvedt G, Dahm KT, Moe RH, Haavardsholm EA, Hagen KB. Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews. Phys Ther. 2007;87(12):1697-715. (Pubitemid 350230760)
19. Jamtvedt G, Dahm KT, Holm I, Flottorp S. Measuring physiotherapy performance in patients with osteoarthritis of the knee: a prospective study. BMC Health Serv Res. 2008;8:145.
20. Metelitsa AI, Green JB. Home-use laser and light devices for the skin: an update. Semin Cutan Med Surg. 2011;30(3):144-7.
21. Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer. 2007;15(10):1145-54. (Pubitemid 47459866)
22. Silva GB, Mendonca EF, Bariani C, Antunes HS, Silva MA. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg. 2011;29(1):27-31.
23. Avram MR, Leonard RT Jr, Epstein ES, Williams JL, Bauman AJ. The current role of laser/light sources in the treatment of male and female pattern hair loss. J Cosmet Laser Ther. 2007;9(1):27-8. (Pubitemid 46581978)
24. Lubart R, Eichler M, Lavi R, Friedman H, Shainberg A. Low-energy laser irradiation promotes cellular redox activity. Photomed Laser Surg. 2005;23(1):3-9. (Pubitemid 40349955)
25. Eells JT, Wong-Riley MT, VerHoeve J, Henry M, Buchman EV, Kane MP, et al. Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. Mitochondrion. 2004;4(5-6):559-67. (Pubitemid 39646806)
26. Pastore D, Greco M, Passarella S. Specific helium-neon laser sensitivity of the purified cytochrome c oxidase. Int J Radiat Biol. 2000;76(6):863-70. (Pubitemid 30352770)
27. Arany PR, Nayak RS, Hallikerimath S, Limaye AM, Kale AD, Kondaiah P. Activation of latent TGF-beta1 by low-power laser in vitro correlates with increased TGF-beta1 levels in laser-enhanced oral wound healing. Wound Repair Regen. 2007;15(6):866-74. (Pubitemid 350135237)
28. de Lima FM, Villaverde AB, Albertini R, Correa JC, Carvalho RL, Munin E, et al. Dual effect of low-level laser therapy (LLLT) on the acute lung inflammation induced by intestinal ischemia and reperfusion: action on anti- and pro-inflammatory cytokines. Lasers Surg Med. 2011;43(5):410-20.
29. Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. 1992;127(3):239-46.
30. Mafra de Lima F, Villaverde AB, Salgado MA, Castro-Faria-Neto HC, Munin E, Albertini R, et al. Low intensity laser therapy (LILT) in vivo acts on the neutrophils recruitment and chemokines/cytokines levels in a model of acute pulmonary inflammation induced by aerosol of lipopolysaccharide from Escherichia coli in rat. J Photochem Photobiol B. 2010;101(3):271-8.
31. Magro CM, Rossi A, Poe J, Manhas-Bhutani S, Sadick N. The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. J Drugs Dermatol. 2011;10(12):1404-11.
32. Sakurai Y, Yamaguchi M, Abiko Y. Inhibitory effect of low-level laser irradiation on LPS-stimulated prostaglandin E2 production and cyclooxygenase-2 in human gingival fibroblasts. Eur J Oral Sci. 2000;108(1):29-34.
33. Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354-62. (Pubitemid 37100262)
34. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85.
35. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. (Pubitemid 38393163)
36. Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40(6 Pt 1):930-7. (Pubitemid 29268924)
37. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555-63. (Pubitemid 29480403)
38. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia: Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 Pt 1):578-89.
39. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D. Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126-1134 e2.